Hyaluronan content governs tissue stiffness in pancreatic islet inflammation

Received for publication, September 27, 2017, and in revised form, November 10, 2017. Published, Papers in Press, November 28, 2017, DOI 10.1074/jbc.RA117.000148

Nadine Nagy‡1, Adi de la Zerda‡, Gernot Kaber‡, Pamela Y. Johnson†, Kenneth H. Hu†, Michael J. Kratochvil‡†, Koshika Yadava†, Wenting Zhao†, Yi Cui§, Guadalupe Navarro†**, Justin P. Annes**, Thomas N. Wight§, Sarah C. Heilshorn¶, Paul L. Bollyky‡, and Manish J. Butte†‡2,3

From the †Department of Medicine, Division of Infectious Diseases, the ‡Department of Materials Science and Engineering, the §Department of Biophysics, the **Department of Medicine, Division of Endocrinology, and the ¶Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Stanford University, Stanford, California 94305 and the ††Matrix Biology Program, Benaroya Research Institute, Seattle, Washington 98101

Edited by Amanda J. Fosang

We have identified a novel role for hyaluronan (HA), an extracellular matrix polymer, in governing the mechanical properties of Islents. We recently reported that insulitis in type 1 diabetes of mice and humans is preceded by intraislet accumulation of HA, a highly hygroscopic polymer. Using the double transgenic DO11.10 × RIPmOVA (DORMo) mouse model of type 1 diabetes, we asked whether autoimmune insulitis was associated with changes in the stiffness of Islets. To measure islet stiffness, we used atomic force microscopy (AFM) and developed a novel “bed of nails”-like approach that uses quartz glass nanopillars to anchor islets, solving a long-standing problem of keeping tissue-scale objects immobilized while performing AFM. We measured stiffness via AFM nanoindentation with a spherical indenter and found that insulitis made islets mechanically soft compared with controls. Conversely, treatment with 4-methylumbelliferylone, a small-molecule inhibitor of HA synthesis, reduced HA accumulation, diminished swelling, and restored basal tissue stiffness. These results indicate that HA content governs the mechanical properties of Islets. In hydrogels with variable HA content, we confirmed that increased HA leads to mechanically softer hydrogels, consistent with our model. In light of recent reports that the insulin production of islets is mechanosensitive, these findings open up an exciting new avenue of research into the fundamental mechanisms by which inflammation impacts local cellular responses.

It was recently reported that pancreatic β-cells are mechanosensitive, i.e. that their viability and function are impacted by their local mechanical environment. In particular, clusters of β-cells derived from mice or from the Min6 β-cell line increase insulin transcription when grown on stiff versus soft substrate (1). However, the relevance of this finding to autoimmune insulitis was unclear because tissue stiffness had not been known to change in the setting of inflammation.

The mechanical properties of tissues are influenced by the constituent cells and extracellular matrix (ECM), as well as their interactions. These include polymer-tangling interactions or cross-linking, both of which are dynamic and are influenced by the molecular mass of the polymers. Viscoelasticity of the matrix is further influenced by the time-dependent movement of matrix fibers and by the movement of water and other solutes. The cells embedded in the matrix add an important influence because of their adhesion (anchoring) and traction on the matrix. However, the mechanical and matrix properties of tissues during inflammation and autoimmunity have not previously been considered, to our knowledge. Moreover, the factors that govern tissue mechanics in the setting of active inflammation and edema are not well-understood.

One factor that we suspected might play a role in tissue mechanics during inflammation is hyaluronan (HA), an ECM glycosaminoglycan that is abundant at sites of both acute and chronic inflammation in a variety of tissues (2, 3). HA is synthesized by three hyaluronan synthase (HAS) enzymes (4). HA levels are greatly elevated in injured tissues, with production increasing by as much as 80-fold over baseline (5, 6). Because HA is highly hygroscopic, this increased HA production seems...
Hyaluronan reduces tissue stiffness in autoimmunity

Figure 1. Autoimmune insulitis is associated with increased islet volume. A, representative dark-field images of isolated islets from 8-week-old control (Balb/c) and DORMO mice. The pictures were taken at a 3.2× (left panels) and 10× (right panels) magnification. B and C, islet size (B) and volume (C) were measured from 20 islets/animal (n = 6 mice/group). D, the number of islets isolated per animal, counted manually. E and G, representative histological staining of insulin (E) and CD3 (G) in pancreas tissue from control and DORMO mice, shown in brown. F and H, average islet area positive for insulin (F) and CD3 (H) staining, evaluated from histologic staining of pancreas tissue from control and DORMO mice. Bars show means ± S.E. *, p < 0.05 versus control by unpaired t-test.

likely to drive edema at sites of injury. Indeed, HA has been implicated in vascular permeability changes (7–9), as well as leukocyte adhesion and egress (10, 11). Many chronic disease processes associated with unremitting inflammation are also associated with prolonged increases in HA, including type 2 diabetes (12), liver cirrhosis (13), and several autoimmune diseases (14, 15).

We chose to evaluate the role of HA in tissue mechanics in autoimmune insulitis, a well-characterized and medically relevant form of inflammation that precedes type 1 diabetes (T1D), in which HA is known to be a prominent feature of the disease (16). In this disease, the immune system attacks and destroys insulin-producing β-cells that reside within pancreatic islets, thereby leaving the affected individual perilously dependent on exogenous insulin for survival (17). Islets themselves are ovoid structures of endocrine tissues that are embedded within the larger, exocrine pancreas. Because islets are well-defined and structurally cohesive units that harbor localized, self-contained inflammation in the setting of autoimmunity, they are well-suited for mechanical analysis. Recently, we reported that autoimmune insulitis was associated with islet-specific deposition of HA in both human T1D (16), as well as in animal models of the disease, including non-obese diabetic mice (18) and DO11.10 × RIPmuOVA (DORMO) mice (19).

In this study we establish the relationship between insulitis-induced depositions of HA in islets and the change in islet stiffness. We measured islet stiffness using atomic force microscopy (AFM) of healthy and insulitis diseased islets. To do so we developed a novel approach for anchoring islets from diabetic and control mice for AFM using quartz glass nanopillars, solving a long-standing problem of keeping tissue-scale objects from moving while performing AFM (20, 21).

Additionally we tested the role of HA in islet stiffness using a specific inhibitor of HA synthesis, 4-methylumbelliferone (4-MU) (22, 23), which was added to the chow of prediabetic mice. We previously demonstrated that this treatment reduced HA levels in both the serum and islets of DORMO mice (19).

Together, these tools allowed us to interrogate the role of HA in tissue stiffness during autoimmune insulitis. In particular, we test the hypothesis that increases in HA content during inflammation promote the softening of inflamed tissues, whereas reductions in HA promote a return to basal levels of stiffness.

Results

Autoimmune insulitis is associated with increased islet volume

We first characterize the size of pancreatic islets during insulitis. To this end, we isolated islets of control Balb/c mice and prediabetic DORMO mice (Fig. 1A). When the islets were examined at a higher magnification, we observed a more irregular shape and an increase in the size of the DORMO islets (Fig. 1A). Analyzing that, we found a 3-fold increase in size (Fig. 1B) and a 2.5-fold increase in islet volume (Fig. 1C) of islets from prediabetic DORMO mice compared with controls. We also found that prediabetic DORMO mice at 8 weeks of age already had a significant decrease in the number of islets, compared with age-matched control mice (Fig. 1D). The functional pancreatic islet characteristics like insulin, produced by β-cells, and glucagon, produced by α-cells, were examined via immunohistochemistry. We saw a significant reduction of insulin-positive staining in the pancreatic islets of the DORMO mice compared with controls (Fig. 1, E and F), whereas the glucagon content in the DORMO mice was only slightly lowered compared with controls (Fig. S1, A and B).

Autoimmune insulitis is prominent in young DORMO mice

The increase in islet size and the loss of insulin-producing β-cells is consistent with the infiltrative nature of autoimmune insulitis. Many of the expected infiltrating cells are CD45+ lymphocytes (24), including T cells (19) and macrophages. Infiltrating cells in and around the DORMO islets were found to express...
CD3, which is the T cell co-receptor involved in the activation of cytotoxic T cells and T helper cells (Fig. 1G). Quantification of the CD3 staining demonstrates that DORmO mice have significantly more CD3-positive infiltrating cells compared with control mice (Fig. 1H). A CD3-positive staining in the control mice could only be detected at sites of vessels inside the islet (Fig. 1G). Furthermore, in the areas of infiltration, a significant increase of macrophages (Fig. S1, C and D) and apoptotic cells (Fig. S1, E and F) could be detected as shown by F4/80 and caspase 3-positive staining. The collective presence of these markers clearly shows the destructive nature of autoimmune insulitis in the DORmO mouse model. These findings implicate the presence of multicellular insulitis and demonstrate that insulitis was present at the time the islets were used in these experiments.

**HA is abundant in autoimmune insulitis**

Our prior work has shown that HA accumulates in human islets during disease (16), as well as in mouse models of T1D (Fig. 2A). We quantified the accumulation of HA in the DORmO T1D mouse model and found a >20-fold increase in 8-week-old prediabetic DORmO mice compared with controls (Fig. 2B). This result agrees with our findings in these mice at other time points. In control mice HA was only found in the adventitial tissue, around the islet capsule, and around vessels inside and outside the islet (Fig. 2A). In contrast, the distribution of HA in the DORmO mice was much more prominent at the sites of invading cells, at the islet borders, and around intraislet vessels (Fig. 2A). Consistent with the increased accumulation of HA around the islet area in the DORmO mice, a significant increase of HA was detected when the whole pancreas was measured and compared with control mice (Fig. 2C).

Looking at transcripts of HASs from isolated islets, we found significant differences in HAS3 expression between islets of DORmO and control mice (Fig. 2F). In contrast, the expression of HAS1 was slightly down-regulated in the DORmO mice (Fig. 2D), and HAS2 was slightly up-regulated (Fig. 2E) compared with control mice. To better understand the accumulation of HA in islets, we examined the role of HA degradation by hyaluronidases (hyal) and found that HYAL1 was down-regulated in isolated islets of DORmO mice, whereas HYAL2 was up-regulated (Fig. S2, A and B). HYAL2 cleaves high molecular mass (HMM)-HA resulting in small HA fragments that are mainly found in inflammatory settings. The increases of HAS3 and HYAL2 found in the pancreatic islets agree with our DORmO mouse model of autoimmune insulitis where inflammation is prominent. Another route by which HA could be degraded is through the action of reactive oxygen species. To investigate whether treatment with 4-MU diminishes HA through this mechanism, we treated INS-1, a β-cell line, with 4-MU and measured intracellular reactive oxygen species. We did not detect an increase in cellular oxidative stress compared with untreated cells (Fig. S2C). These results show that HA accumulation and its associated inflammation in diabetes are due to a combination of increased synthesis and cleavage of HA but not reactive oxygen.
Hyaluronan reduces tissue stiffness in autoimmunity

We also investigated CD44, the major cell surface receptor of HA. Similar to HA, CD44 accumulation and distribution could mainly be detected in mice with autoimmune insulitis (Fig. S1G). CD44-positive staining showed a 20-fold increase in the DORmO islets compared with control mice (Fig. S1H).

Autoimmune insulitis is associated with accumulation of low molecular mass (LMM)-HA fragments

Measuring the HA size in isolated pancreatic islets from control mice and treated and untreated DORmO mice via size exclusion column revealed three very different profiles. The peak of the curve for control mice was found at lower $K_w$, compared with DORmO mice, meaning the HA found in the isolated control islets mainly consist of HMM-HA (Fig. 2G). The peak of the untreated DORmO curve on the other hand was at higher $K_w$, meaning that predominately LMM HA was found in those isolated islets (Fig. 2G). The peak and the whole curve of the 4-MU–treated DORmO mice lies in between the controls and untreated DORmO mice, meaning that the 4-MU–treated DORmO mice islets shift from LMM-HA in the direction of HMM-HA (Fig. 2G). We also observed that the total amount of HA is lower in 4-MU–treated DORmO islets compared with untreated DORmO islets (Fig. 2G). Furthermore, we investigated the effect of HMM-HA and LMM-HA on T cell proliferation in different diabetic conditions. HA sizes between 50 kDa and 1.8 MDa had no impact on T cell proliferation in the different glucose conditions (Fig. S3). Even a hyaluronidase digestion of 100 kDa did not show any effect on T cell proliferation (Fig. S3). Taken together, these results show that inflamed islets accumulate fragmented, inflammatory HA, whereas 4-MU treatment reduces this effect.

HA inhibition prevents mice from becoming hyperglycemic

Having established that HA is abundant at sites of autoimmune insulitis, we examined the effect of HA inhibition on insulitis progression in T1D. To achieve that, we used the small molecule inhibitor 4-MU (Fig. 3A), which was administered orally to the mice, at a dose shown to be effective before (19). 4-MU treatment beginning at 5 weeks of age appeared to stop the progression of diabetes as compared with untreated controls (Fig. 3B). Additionally 4-MU–treated DORmO mice had significant more insulin-positive areas (Fig. 3, C and D) and significantly fewer HA-positive areas (Fig. 3, E and F) in the pancreatic islets compared with untreated controls, as shown and quantified by immunohistochemistry. Because 4-MU is primarily metabolized in the liver when administered orally, we investigated the influence of 4-MU on liver function. A liver panel with aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, $\gamma$-glutamyl transference, and total and direct bilirubin was measured in the serum from control and prediabetic DORmO mice with and without 4-MU treatment (Fig. S4). All markers showed no difference between the treatment groups. Alkaline phosphatase and $\gamma$-glutamyl transference were not detected in either group (data not shown). Aminotransferase was a little higher in the control animals compared with DORmO mice, but there was no difference caused by 4-MU treatment in either mouse group (Fig. S4). Total and direct bilirubin were slightly elevated in the 4-MU treatment groups, but the difference was not significant (Fig. S4). These results indicate that 4-MU does not cause hepatocyte toxicity or cholestasis.

Nanopillar preparation of islet AFM samples

To study whether the changes in morphology and chemical composition resulted in a mechanical change in the islets, we examined the elastic modulus of islets by AFM. It has been a long-standing problem to anchor and measure soft tissue samples, particularly in the size regime of islets. Epoxies can permeate the tissue samples and artificially increase the measured stiffness (21). Clamps or plates can result in squeezing fluids from one part of the tissue into another. These effects could...
especially distort the measured elasticity of tissues rich with HA.

We developed an innovative approach for anchoring islets that involves attaching them upon nanopillars. Sharp nanopillar-decorated surfaces similar to the ones used in this study have been previously shown to impair cell movement at the single cell level (25). If the impalement is relative shallow compared with the size of the tissue, it will prevent sample movement while leaving the upper surface of the tissue mechanically unaltered for measurement by AFM. We prepared an array of cylindrical nanopillars on quartz glass using electron beam lithography and deep reactive-ion etching (Fig. 4A) (26). The nanopillars arose from a glass base and were characterized by scanning electron microscopy (Fig. 4B). We attached the glass base of the nanopillars onto the bottom of a Petri dish by double-sided tape before carefully placing islets onto the pillars. Gentle centrifugation of the islets on the pillars was used to fix samples in place without damaging the samples (see “Experimental procedures”) (Fig. 4C). The islets were then transfixed and did not move with tilting of the Petri dish.

HA leads to mechanically soft islet tissue

We performed AFM on islets obtained from healthy control mice (Fig. 4D). We chose a spherical colloidal probe to reduce the chance of piercing the soft islet matrix and to perform spatial averaging. Based on visual examination, indentation measurements were chosen to occur in the flat, “top” region of each islet, thus minimizing chances of a collision between the cantilever base and the islet. Force-distance map measurements were performed, and each control mouse islet was measured a median of ~32 times (n = 5 islets). Elastic moduli calculated from each islet were graphed as smoothed histograms (Fig. 4E). The elasticity of each islet measured spanned a range from 100 Pa to 10 kPa, with an average of 3,039 Pa (Fig. 4E, vertical black line). These results indicate that the mechanical stiffness of healthy islets is ~3 kPa.

4-MU treatment makes inflamed islets stiffer

We next performed AFM on islets isolated from prediabetic DORmO mice that had been fed with control chow or 4-MU chow (Fig. 5A) for at least 2 weeks. Force-distance map mea-
measurements were performed, and each islet was measured an average of 166 times each (n = 6 islets in each group). We found the islets from prediabetic DORmO mice had a mean elastic modulus of 284 Pa (Fig. 5B, vertical bar). Thus, the accumulation of HA in these prediabetic islets led to a significant decrease of mechanical stiffness compared with healthy mice. On the other hand, 4-MU–treated DORmO mice had a mean modulus of 587 Pa (Fig. 5B) approximately twice as stiff as the non-treated DORmO mice islets. In a second independent experiment (n = 9 control chow, n = 11 4-MU chow), the islets from 4-MU–fed DORmO mice were again statistically significantly stiffer than those from DORmO mice fed control chow (p = 0.01). Thus, reducing accumulation of HA with 4-MU results in partial restoration of mechanical stiffness. These findings show that accumulation of HA in the islets results in mechanical softening of the tissues and that treatment with an inhibitor of HA synthesis partially rescues the tissue mechanical properties to that of healthy, non-insulitis islets.

We then examined the effects of 4-MU on the stiffness of islets isolated from control animals without insulitis. Stiffness of islets from control Balb/c mice did not change significantly after feeding 4-MU chow (Fig. 5C). These results indicate that 4-MU does not alter the mechanical properties of islets in the absence of inflammation. In light of our previous report that healthy islets contain only minimal HA (19), these data are consistent with the model that 4-MU-mediated effects on islet stiffness are mediated through effects on HA.
Increased HA content leads to mechanically softer hydrogel tissue models

Having established that the increase of water is associated with higher HA content in islets, we now wanted to investigate the role of hyaluronan concentration in altering the mechanical properties of hydrogels that model the mechanical behavior of tissues. We examined Matrigel mixed with different concentrations of 100-kDa HA. The final concentration of HA in the hydrogels were 25, 12.5, and 0% (by weight), respectively, with a constant concentration of Matrigel in each and total volume. Using shear rheology, we found that all HA-containing gels were softer than unmodified Matrigel (Fig. 6A). The highest HA-concentration gel showed a decrease of ~45% in the Young’s modulus (~110 Pa) compared with the unmodified Matrigel (Fig. 6A).

In a separate experiment we added hyal-digested HA at the same concentrations as used before. We found that the hyal-treated HA hydrogels were even softer than the untreated HA hydrogels independent of the containing HA concentration (Fig. 6B), suggesting that reduced polymer size contributes to softening of hydrogels.

In a second model system, we used a thiolated collagen-based hydrogel system covalently cross-linked with PEG-based linker. Similar to before, this system was doped with various amounts of HA while maintaining the same concentration of the collagen component and cross-linker density. The stiffness properties of these materials were measured in PBS buffer with AFM, the same technique used for measuring islet stiffnesses. Using AFM with the HA hydrogels, we observed similar trends, with increasing HA concentration resulting in softer hydrogels (Fig. 6C).

Discussion

We report here that inflamed islets are softer than healthy islets and that increases in local content of HA are a major driver of tissue stiffness. This paper is the first study to our knowledge to 1) examine the tissue mechanics of islets, 2) quantify effects of inflammation on local tissue mechanics, and 3) implicate HA in tissue biomechanics. Given the recent report that primary β-cells are mechanosensitive and alter their insulin production in response to tissue stiffness (1), these findings here may provide a critical link between inflammation and β-cell dysfunction in T1D.

Along with decreasing stiffness in inflamed islets, we find that increased HA content and reduced HA size both lead to a decrease in hydrogel stiffness. This is consistent with previous reports showing that increased HA concentration within HA collagen hydrogels significantly decreased shear storage modulus and increased compressive resistance (34). Those authors reported that HA-induced effects on viscoelastic properties result primarily from modulation of the interstitial fluid. Other studies suggest that HA influences islet cell biology in multiple ways, including effects on insulin release and viability (28–32).

Our model is that increased HA content reduces tissue stiffness through effects on the organization of water. It is well-established that networks of charged glycosaminoglycan polymers, like HA, trap water and restrict its movement. For this reason, HA is a common component of hydrogels (27). Further, the content of HA within a hydrogel is known to be related to its viscosity (33, 34) and stiffness (27, 35). Similarly, increased HA content within tissues is known to cause them to swell, resulting in edema (36). We propose that the hydroscopic properties of HA may recruit and order water molecules within tissues and hydrogels, thus acting as a cushioning and lowering the stiffness properties in these cases. LMM-HA may enhance this softening because the movement and fluidity of shorter HA polymers can be expected to be more fluid. HA and LMM-HA in particular may thereby be a major contributor to the mechanical properties of inflamed tissues, including islets under autoimmune attack.

Inflamed islets are mechanically soft, and this may be relevant to the pathophysiology of autoimmune insulitis. It was recently reported that stiffness modulates T lymphocyte migra-
Hyaluronan reduces tissue stiffness in autoimmunity

...tion and morphological changes induced by TCR/CD3 triggering (44). Softer materials were recently reported to increase insulin mRNA expression of 3D primary mouse islet-derived and Min6-derived β-cell clusters (45).

It is well-known that physiological processes within inflamed tissues are affected by the stiffness of the ECM, which can affect many of the biological activities of the cells living within. For example, stem cells alter their differentiation and even their capacity for self-renewal and differentiation based on the elasticity of the tissue (37, 38). Cancer cells alter their proliferation and metastatic potential based on the mechanical properties of the matrix (39, 40). We recently showed that the speed of migrating T cells, like many circulating immune cells, is influenced by the presence of HA (41). Other factors include the porosity and mechanics of the tissue (42). We are currently working to understand how tissue stiffness impacts the production and secretion of insulin and other endocrine hormones produced by islets. Of note, we recently reported that 4-MU did not affect serum insulin levels in Balb/C mice (17). Thus, the rescue of insulin production in the islets by 4-MU is specific to diabetes.

Reducing the accumulation of HA in T1D using the small-molecule inhibitor 4-MU results in a return to basal levels of mechanical stiffness. Having previously reported that this same treatment promotes the resolution of autoimmunity (19), we suggest that HA and mechanically soft islets may play a fundamental mechanism in engendering autoimmunity. 4-MU reduces accumulation of HA in other autoimmune diseases such as experimental autoimmune encephalomyelitis (41, 43), the mouse model of multiple sclerosis, and it is tempting to speculate that T cell responses in T1D (19) and experimental autoimmune encephalomyelitis are reduced because of 4-MU— and HA-mediated effects on tissue mechanics. However, HA inhibition and 4-MU have other effects in addition to fluid shifts (reviewed in Ref. 23), and the relative importance of these to immune activation has not yet been elucidated. Also, 4-MU may have spasmytic and choleric activities that are not linked to the activities of HA syntheses. The importance of tissue mechanics in cellular differentiation and cancer metastasis has been well-established, but this work is the first to posit a role in autoimmunity.

The development of nanopillars to anchor islets in place is an innovative solution to the challenge of performing AFM on these tissues. We chose a large colloidal indenter and utilized modest indentations to reduce the influence of the structures situated beneath the ECM. However, the AFM measurements here entailed in situ measurements of the islet ECM but may amalgamate the mechanical influence of underlying cells or other structures.

This study has a few limitations. First, we have not investigated the contributions of HA-binding proteins (hyaladherins) to HA-mediated effects on tissue stiffness. Hyaladherins, including TSG-6 (TNF-stimulated gene-6), and inter-α-inhibitor, play critical roles in determining the longevity, size, and architecture of HA in tissues (44). These molecules could therefore be expected to influence tissue stiffness along with HA (45). Indeed, the catabolism of HA plays an important role in tissue homeostasis versus inflammation because HMM-HA and LMM-HA activate different receptors (46). Indeed, high-molecular-weight HA is anti-inflammatory and promotes resolution of local immune responses (46). Here we show that 4-MU alters this balance, shifting the LMM-HA in the direction of HMM-HA.

Moreover, many other cellular (47) and ECM components (16, 19, 48) of pancreatic islets might further impact the mechanical properties of islets during both health and disease. Along with water movement, increased cellularity caused by the abundance of activated CD4+CD44+ T cells may also contribute to the mechanical changes. Matrix components, such as glycosaminoglycans, are ionically charged and can electrostatically trap the diffusion cytokines and molecules in the matrix (49–51).

In conclusion, islets of autoimmune diabetes are mechanically soft because of accumulation of HA. Understanding what regulates changes in the matrix components may be of critical importance to appreciate why tissue-specific autoimmune diseases arise in the first place. Thus, understanding whether tissue factors such as matrix stiffness promote ongoing autoimmunity opens the opportunity to intervene and prevent autoimmunity, perhaps with small-molecule inhibitors like 4-MU. This new perspective opens the possibility of developing other treatments that target the mechanical properties of tissues in T cell–mediated diseases.

Experimental procedures

Mice

All animals were bred and maintained under specific pathogen-free conditions, with free access to food and water, in the vivarium at the Benaroya Research Institute or in the animal facilities at Stanford University. Balb/c and DO11.10 transgenic mice were purchased from The Jackson Laboratory and bred with Balb/c mice expressing RIPmOVA (made available from the Benaroya Research Institute) to generate the DORMO double-transgenic mice.

4-MU treatment

4-MU (Alfa Aesar) was pressed into the mouse chow by TestDiet® and irradiated before shipment, as previously described (10). We previously determined that this chow formulation delivers 250 mg/mouse/day, yielding a plasma drug concentration of 640.3 ± 17.2 nmol/liter in mice, as measured by HPLC-MS. Mice were initiated on the 4-MU chow at 6 weeks of age and were maintained on this diet until they were euthanized, unless otherwise noted.

Weight and diabetes monitoring

Beginning at 4 weeks of age, mice were weighed weekly as well as bled via the tail tip for the determination of their blood glucose level using a Contour blood glucose meter and blood glucose monitoring strips (Bayer Healthcare). When two consecutive blood glucose readings of 250 mg/dl or greater were recorded, the mice were considered diabetic. When two consecutive blood glucose readings of 300 mg/dl or greater were recorded, mice were euthanized.
Hyaluronan reduces tissue stiffness in autoimmunity

**Serum measurements**

Mouse serum was obtained from 15-week-old mice if not indicated otherwise. Serum samples for the liver panel were measured by the Animal Diagnostic Laboratory at the Stanford School of Medicine. Analyses for the mouse liver panel were performed on a Dimension Xpand (Siemens) analyzer.

**Islet isolation**

Islets were isolated as described (52). Briefly, mice 8 weeks of age were anesthetized with 2,2,2-tribromoethanol in PBS. The bile duct was clamped at its distal (intestinal) end and a 30-gauge needle was used to inflate each pancreas through the common bile duct with 4 ml of islet medium comprising RPMI 1640 containing 1.0 g of NaHCO₃, 10% FBS (S12450H; Atlanta Biologicals), 1 mM sodium pyruvate, and penicillin/streptomycin at 4 °C. The islet medium was supplemented with 0.8 mg/ml of collagenase P (11-249-002-001; Roche) and filtered (0.22-μm filter) prior to injection. Subsequently, two or three excised pancreata were placed in separate 50-ml conical centrifuge tubes and incubated in 5 ml of islet medium for 13 min at 37 °C. The medium was then decanted, fresh 4 °C islet medium was added, and the tubes were shaken vigorously to disrupt the pancreata. The tissue suspensions were filtered through a 30-mesh metal screen to remove large debris, the filtrates were pelleted by centrifugation, and the pellets were resuspended in 4 °C islet medium. The material was centrifuged through Histopaque 1077 to isolate the islets, which were washed and hand-picked before being resuspended in islet medium and maintained in a tissue culture incubator.

**Tissue processing and imaging**

Tissues for histochemistry were taken out of the animals and immediately transferred into 10% neutral buffered formalin or 5-methyl Carnoy’s solution. The tissue was processed to paraffin immediately transferred into 10% neutral buffered formalin or Tissue processing and imaging 4°C islet medium. The material was centrifuged through Histopaque 1077 to isolate the islets, which were washed and hand-picked before being resuspended in islet medium and maintained in a tissue culture incubator.

**Quantitative PCR**

Islets were harvested for total RNA isolation using the High Pure RNA isolation kit (Roche Applied Science) and reverse-transcribed using the high capacity cDNA reverse transcription kit (Applied Biosystems). For quantitative PCR, all reagents were supplied by Applied Biosystems, unless otherwise noted. Relative quantification of HAS1, HAS2, HAS3, HYAL1, and HYAL2 gene expression was performed using TaqMan gene expression assays: HAS1, Mm00468496_m1; HAS2, Mm00515089_m1; HAS3, Mm00515092_m1 HYAL1, Mm00467206_m1; and HYAL2, Mm01230689_g1, respectively. Briefly, 100 ng of cDNA was amplified in 1× TaqMan gene expression master mix with a 250 nM TaqMan probe in a 20-μl reaction. Data for mRNA expression are provided as means ± S.E. of the estimated copy number, normalized to 18S rRNA, and differences between enriched primary islet cell populations were analyzed.
Oxidative stress detection

INS-1 cells, a β-cell line, were treated with and without 300 μM 4-MU for 24 h. At the end of treatment, a CellROX® reagent (Thermo Fisher) was added for measuring cellular oxidative stress. Using flow cytometry, the MFI for the oxidative stress marker in the different treatment groups was calculated.

T cell proliferation

CD4+ T cells were positively selected from spleens and lymph nodes of naïve 10-bit C57Bl6 mice using MACS kits and labeled with carboxyfluorescein succinimidyl (CFSE) (Thermo Fisher) as per manufacturer recommendation. CFSE-labeled CD4+ T cells were stimulated for 72 h with 2 μg/ml of concanavalin A in the presence of T cell depleted, irradiated APCs in 96-well round bottom plates. HA (Lifecore) of indicated sizes was added to the culture at 20 μg/ml final concentration. At the end of 72 h, proliferation was measured by the dilution of CFSE-labeled CD4+ T cells on an LSR II flow cytometer. Proliferation index was calculated using FlowJo (Treestar version 9).

Atomic force microscopy

Islets were taken from prediabetic DORmO mice or control (Balb/c) mice treated with 4-MU or control chow for at least 2 weeks. The islets were fixed using 4% PFA for 15 min at room temperature and washed three times with PBS. AFM measurements required the islets to be stable and not moving while measuring. To anchor islets, we used a nanopillar array. The substrates consist of a regular array of vertical quartz nanopillars, fabricated on quartz coverslips (26) and taped to the bottom of a Fluorodish Petri dish (World Precision Instruments). The diameter of each pillar was ~200 nm, whereas the length of each pillar was ~1 μm, and the distance between pillars was 3 μm. Because the nanopillars are small, they are not visible through a low magnification objective (e.g. 20×). To facilitate localization of the pillars, we fabricated a 5-μm × 5-μm square for each set of 33 × 33 nanopillars (Fig. 4C). We placed ~5 μl of fixed islets in PBS onto the center of the nanopillar array, which was spun down (100 rpm, 2 min) onto the nanopillars. For islets that were unable to be anchored on nanopillars, they were gently spun onto polylysine-coated Fluorodishes and confirmed to be anchored to the plate by gentle rocking. After confirming islets were anchored, 3 μl of PBS at room temperature was added to the Petri dish. Islets (n = 15) were interrogated by using AFM (MFP-3D Bio; Asylum Research). We employed a Si with a 5–10-μm colloidal borosilicate glass bead probe (HYDRA2R-100NG-BSG-5 or HYDRA6R-200NG-BSG-10; AppNano). Islets were gently indented in contact mode by the cantilever tip with a trigger force of 500 pN. Deflection data were converted to force by multiplying by the spring constant. To measure Young’s modulus, we examined the indentation during extension of the tip into the sample. We fit the function of force versus indentation distance by using the Hertz model, using code in the Asylum Research software. We used a Poisson’s value of 0.5 for the islets and otherwise default parameters. Stiffness data were imported into R for statistical analysis. Permutation testing was used for statistical comparisons (54).

Hydrogels

Growth factor–reduced Matrigel matrix basal membrane (Corning; Bedford, MA) was diluted to a concentration of 7.5 mg/ml using MilliQ water (H2O∞, filtered to a resistance of 18.2 MΩ) with 100-kDa sodium hyaluronate (Lifecore Biomedical, Chaska, MN) to achieve final HA weight of 25, 12.5, and 0% (compared with total polymer) while maintaining the equivalent total volumes for each condition. All solutions were kept on ice throughout the preparation. Dynamic oscillatory rheological measurements were conducted with an ARG2 rheometer (TA Instruments, New Castle, DE) with a 20-mm diameter 1° cone angle geometry at a stage temperature of 37 °C. Upon the gel reaching thermal equilibrium, 3-min time sweeps at 10 Hz and 5% strain were conducted on 40-μl samples. Reported data are the result of the average storage modulus (G’) from three time sweeps, reported as Young’s modulus using the equation of E (Young’s modulus) = 2G’(1 + ν), assuming a Poisson’s ratio of ν = 0.5 for hydrogels.

Cross-linked hydrogels were formulated using the commercially available thiolated collagen Gelin-S and PEGDA cross-linker Extralink (ESI BIO, Alameda, CA). Gelin-S was reconstituted, and Extralink were reconstituted to 2× and 1× according to manufacturer’s specifications, respectively. Gelin-S solutions were mixed with 100-kDa sodium hyaluronate in H2O∞ to form ratios of 25, 12.5, and 0% (sodium hyaluronate:Gelin-S by weight) ensuring same total volume for each formulation. Extralink was added to the solutions following manufacturer recommendations, and 10 μl of hydrogel solution was cast onto fluorodish sample chambers and allowed to cure. PBS buffer was added to the hydrogels to ensure fully hydrated hydrogels prior to AFM measurements. Measurements were conducted as previously described for the pancreatic islets.

Statistics

All other data are expressed as means ± S.E. of n independent measurements. The comparison between two groups was performed with unpaired t tests. A p value < 0.05 was considered statistically significant. Data analysis was performed with the use of GraphPad Prism 5.0 software.

Author contributions—N. N., P. L. B., and M. J. B. conceptualization; N. N., J. P. A., T. N. W., and S. C. H. data curation; N. N., Y. C., J. P. A., T. N. W., S. C. H., P. L. B., and M. J. B. supervision; N. N., P. L. B., and M. J. B. funding acquisition; N. N., A. d. I. Z., G. K., P. Y. J., K. H. H., M. J. K., K. Y., W. Z., G. N., J. P. A., and M. J. B. investigation; N. N., G. K., K. H. H., M. J. K., K. Y., J. P. A., P. L. B., and M. J. B. visualization; N. N., G. K., Y. C., J. P. A., and P. L. B. methodology; N. N., P. L. B., and M. J. B. writing-original draft; N. N., P. L. B., and M. J. B. project administration; N. N., G. K., Y. C., J. P. A., T. N. W., S. C. H., P. L. B., and M. J. B. writing-review and editing; G. K. and K. Y. validation.

References

1. Nyitray, C. E., Chavez, M. G., and Desai, T. A. (2014) Compliant 3D microenvironment improves β-cell cluster insulin expression through mechanosensing and β-catenin signaling. Tissue Eng. Part A 20, 1888–1895 CrossRef Medline
2. Jiang, D., Liang, J., and Noble, P. W. (2011) Hyaluronan as an immune regulator in human diseases. *Physiol. Rev.* **91**, 221–264 CrossRef Medline

3. Laurent, T. C., Laurent, U. B., and Fraser, J. R. (1996) The structure and function of hyaluronan: an overview. *Immunol. Cell Biol.* **74**, A1–A7 CrossRef Medline

4. Vigetti, D., Karousou, E., Viola, M., Deleoniub, S., De Luca, G., and Passi, A. (2014) Hyaluronan: biosynthesis and signaling. *Biochim. Biophys. Acta* **1840**, 2452–2459 CrossRef Medline

5. Fraser, J. R., Laurent, T. C., and Laurent, U. B. (1997) Function of hyaluronan binding protein 2 is a novel regulator of vascular integrity. *Arterioscler. Thromb. Vasc. Biol.* **30**, 483–490 CrossRef Medline

6. Singleton, P. A., Mrazek-pazova, T., Guo, Y., Sammani, S., Mambetsariev, N., Lennon, F. E., Garcia, J. G., and Singleton, P. A. (2010) Hyaluronan binding protein 2 is a novel regulator of vascular integrity. *Arterioscler. Thromb. Vasc. Biol.* **30**, 483–490 CrossRef Medline

7. Jiang, D., Liang, J., and Noble, P. W. (2011) Hyaluronan as an immune regulator in human diseases. *Physiol. Rev.* **91**, 221–264 CrossRef Medline

8. Lennon, F. E., Garcia, J. G., and Singleton, P. A. (2010) Inhibition of hyaluronan synthesis accelerates murine atherosclerosis: novel insights into the role of hyaluronan synthesis. *Circulation* **122**, 2313–2322 CrossRef Medline

9. Valva, P., Cacciato, P., Diaz Carrasco, J. M., Gadano, A., Galdame, O., Valva, P., Cacciato, P., Diaz Carrasco, J. M., Gadano, A., Galdame, O., Galoppo, M. C., Mullen, E., Andonegui, G., Ruffell, B., Johnson, P., and Kubes, P. (2004) Role of CD44 and hyaluronan in neutrophil recruitment. *J. Immunol.* **173**, 7594–7601 CrossRef Medline

10. Mambetsariev, N., Mambetsariev, B., Sammani, S., Lennon, F. E., Garcia, J. G., and Singleton, P. A. (2010) Hyaluronan binding protein 2 is a novel regulator of vascular integrity. *Arterioscler. Thromb. Vasc. Biol.* **30**, 483–490 CrossRef Medline

11. Harrington, S., Williams, J., Rawal, S., Ramachandran, K., and Stehno-Bittel, L. (2017) Hyaluronic acid/collagen hydrogel as an alternative to derived hydrogels for three-dimensional cell culture and tumor xenografts. *Curr. Protoc. Cell Biol.* Chapter 10, Unit 10.14 Medline

12. Assav-Asherie, N., Sever, D., Bogdani, M., Johnson, P., Weiss, T., Ginzberg, A., Perles, S., Weiss, L., Sebban, L. E., Turley, E. A., Okon, E., Raz, I., and Naor, D. (2015) Can CD44 be a mediator of cell destruction?: The challenge of type 1 diabetes. *PLoS One* **10**, e0143589 Medline

13. Kato, Y., Mukudai, Y., Okimura, A., Shimazu, A., and Nakamura, S. (1995) Hyaluronan reduces tissue stiffness in autoimmunity. *Arthritis Rheum.* **38**, 1160–1170 CrossRef Medline

14. Bittel, L. (2017) *Hyaluronan: biosynthesis and signaling.* A1–A7 CrossRef Medline

15. Tan, K. H., Y. G., K. A., S. A., Z., Y., and C. S. T. (2018) Hyaluronan: a mediator of islet dysfunction and destruction in diabetes? *J. Rheumatol.* **45**, 158–159 CrossRef Medline

16. Responde, D. J., M. R., and A. K. A. (2012) Identification of potential biophysical and molecular signalling mechanisms underlying hyaluronan acid enhancement of cartilage formation. *J. Soc. Interface* **9**, 3564–3573 CrossRef Medline

17. Rehfeldt, F., Brown, A. E., Raab, M., Cai, S., Zajac, A. L., Zemel, A., and Discher, D. E. (2012) Hyaluronan acid matrices show matrix stiffness in 2D and 3D dictates cytoskeletal order and myosin-II phosphorylation within stem cells. *Integr. Biol. (Camb)* **4**, 422–430 Medline

18. Schren, H. R., Chhaya, V. H., Greenwald, S. E., Bader, D. L., Lee, D. A., and Shelton, J. C. (2006) The influence of swelling and matrix degradation on
Hydrogels such as alginate, collagen, and gelatin have been extensively studied for their potential as injectable biomaterials for tissue engineering and regenerative medicine applications. These hydrogels provide a physical scaffold that can support cell adhesion, proliferation, and differentiation, thereby facilitating tissue repair and regeneration. However, the physicochemical properties of hydrogels, such as their mechanical stiffness and gelation time, can significantly influence their biological performance. For example, hydrogels with lower stiffness may allow for better cell infiltration and matrix deposition, whereas hydrogels with higher stiffness can induce more pronounced effects on cell morphology and function. Cell culture studies have shown that hydrogel stiffness influences cellular behavior, including cell survival, proliferation, and migration. In Figure 1, we demonstrate the dependence of cell survival on hydrogel stiffness, where a lower stiffness hydrogel supports higher cell survival compared to a stiffer hydrogel. These findings underscore the importance of tailoring hydrogel properties to specific tissue engineering applications to achieve desired biological outcomes. Overall, the functional properties of hydrogels, including their mechanical stiffness, are critical factors that need to be considered in the design and development of injectable biomaterials for tissue engineering.